Clinical Implications of Precision Genomics

Abstract

Precision genomics -- the use of individual genomic information to guide clinical decision-making -- has matured from a research curiosity into a clinical reality, with over 400 FDA-recognised pharmacogenomic drug-gene pairs, national genomic medicine programmes in 14 European countries, and whole-genome sequencing costs falling below EUR 200. Yet clinical implementation lags far behind scientific capability: fewer than 15% of European patients prescribed drugs with well-validated pharmacogenomic interactions receive pre-emptive genotyping, and the translation of genomic risk scores into preventive care remains embryonic. We evaluated five precision genomics implementation frameworks across 42,648 patients enrolled in genomic medicine programmes at five European centres (Vienna, Stockholm, Madrid, Paris, and Tallinn) from 2016 to 2022, covering pharmacogenomics, hereditary cancer syndromes, rare disease diagnosis, polygenic risk scores for common diseases, and somatic tumour genomics. We compared: reactive single-gene testing, pre-emptive pharmacogenomic panels, comprehensive germline sequencing with clinical decision support, integrated germline-somatic analysis, and ML-augmented genomic interpretation with automated clinical reporting. Our Precision Genomics Implementation Score (PGIS) integrates diagnostic/therapeutic yield, turnaround time, clinical actionability, patient comprehension, and health system integration. ML-augmented genomic interpretation achieved the highest PGIS (0.930) by reducing variant interpretation time from 4.2 hours to 28 minutes while maintaining concordance with expert classification at 96.8%, while pre-emptive pharmacogenomic panels (PGIS 0.914) demonstrated the highest immediate clinical impact by preventing 62% of predicted adverse drug reactions in genotyped patients.